126 related articles for article (PubMed ID: 30949858)
1. HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model.
Schardt JS; Noonan-Shueh M; Oubaid JM; Pottash AE; Williams SC; Hussain A; Lapidus RG; Lipkowitz S; Jay SM
AAPS J; 2019 Apr; 21(3):48. PubMed ID: 30949858
[TBL] [Abstract][Full Text] [Related]
2. Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.
Schardt JS; Oubaid JM; Williams SC; Howard JL; Aloimonos CM; Bookstaver ML; Lamichhane TN; Sokic S; Liyasova MS; O'Neill M; Andresson T; Hussain A; Lipkowitz S; Jay SM
Mol Pharm; 2017 Apr; 14(4):1047-1056. PubMed ID: 28248115
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
4. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
[TBL] [Abstract][Full Text] [Related]
5. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
6. Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
Zhou S; Wang R; Xiao H
Oncol Rep; 2020 Sep; 44(3):927-938. PubMed ID: 32705217
[TBL] [Abstract][Full Text] [Related]
7. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
[TBL] [Abstract][Full Text] [Related]
8. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
11. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.
Brunckhorst MK; Lerner D; Wang S; Yu Q
Cancer Biol Ther; 2012 Jul; 13(9):804-11. PubMed ID: 22669575
[TBL] [Abstract][Full Text] [Related]
12. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Verma N; Müller AK; Kothari C; Panayotopoulou E; Kedan A; Selitrennik M; Mills GB; Nguyen LK; Shin S; Karn T; Holtrich U; Lev S
Cancer Res; 2017 Jan; 77(1):86-99. PubMed ID: 27793840
[TBL] [Abstract][Full Text] [Related]
13. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
14. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
[TBL] [Abstract][Full Text] [Related]
15. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
[TBL] [Abstract][Full Text] [Related]
16. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
17. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
18. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
19. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
20. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
